Literature DB >> 12884072

Antifungal activity of nonantifungal drugs.

J Afeltra1, P E Verweij.   

Abstract

The antifungal activity of synthetic, nonchemotherapeutic compounds, antineoplastic agents and antibacterial drugs, such as sulphonamides, has been known since the early 20th century (1932). In this context, the term "nonantifungal" is taken to include a variety of compounds that are employed in the management of pathological conditions of nonfungal infectious etiology but have been shown to exhibit broad-spectrum antifungal activity. In this review, the antifungal properties of compounds such as chlorpromazine, proton pump inhibitors, antiarrhythmic agents, cholesterol-lowering agents, antineoplastic and immunosuppressive agents, antiparasitic drugs and antibiotics are described. Since fungi are eukaryotic cells, they share many pathways with human cells, thus increasing the probability of antifungal activity of "nonfungal drugs". The potential of these drugs for treatment of fungal infections has been investigated sporadically using the drugs alone or in combination with "classic" antifungal agents. A review of the literature, supplemented with a number of more recent investigations, suggests that some of these compounds enhance the activity of conventional antifungal agents, eliminate natural resistance to specific antifungal drugs (reversal of resistance) or exhibit strong activity against certain fungal strains in vitro and in animal models. The role of these agents in the epidemiology and in the clinical manifestations of fungal infections and the potential of certain drugs for treatment of invasive fungal infections require further investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884072     DOI: 10.1007/s10096-003-0947-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  100 in total

1.  Prevention of invasive aspergillosis in AIDS by sulfamethoxazole.

Authors:  J Afeltra; J F Meis; J W Mouton; P E Verweij
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

Review 2.  The plasma membrane H(+)-ATPase of fungi. A candidate drug target?

Authors:  D S Perlin; D Seto-Young; B C Monk
Journal:  Ann N Y Acad Sci       Date:  1997-11-03       Impact factor: 5.691

3.  Fungicidal activity of cecropin A.

Authors:  A J DeLucca; J M Bland; T J Jacks; C Grimm; T E Cleveland; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  Combined amphotericin B-tetracycline therapy for experimental coccidioidomycosis.

Authors:  M Huppert; S H Sun; K R Vukovich
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

Review 5.  Fungal plasma membrane proton pumps as promising new antifungal targets.

Authors:  B C Monk; D S Perlin
Journal:  Crit Rev Microbiol       Date:  1994       Impact factor: 7.624

6.  The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis.

Authors:  C J Clancy; M H Nguyen
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

7.  Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis.

Authors:  S L Newman; L Gootee; G Brunner; G S Deepe
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  Effects of the combination of ketoconazole and calcium channel antagonists against Candida albicans in vitro.

Authors:  E Krajewska-Kułak; W Niczyporuk
Journal:  Arzneimittelforschung       Date:  1993-07

9.  In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles.

Authors:  M Del Poeta; W A Schell; C C Dykstra; S K Jones; R R Tidwell; A Kumar; D W Boykin; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi.

Authors:  R Nakajima; A Kitamura; K Someya; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  11 in total

1.  Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.

Authors:  Ronen Ben-Ami; Keren Olshtain-Pops; Michal Krieger; Ilana Oren; Jihad Bishara; Michael Dan; Yonit Wiener-Well; Miriam Weinberger; Oren Zimhony; Michal Chowers; Gabriel Weber; Israel Potasman; Bibiana Chazan; Imad Kassis; Itamar Shalit; Colin Block; Nathan Keller; Dimitrios P Kontoyiannis; Michael Giladi
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

Review 2.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

3.  In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum.

Authors:  Francielli P K Jesus; Laerte Ferreiro; Érico S Loreto; Maiara B Pilotto; Aline Ludwig; Karine Bizzi; Juliana S M Tondolo; Régis A Zanette; Sydney H Alves; Janio M Santurio
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

4.  Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.

Authors:  Rossana de Aguiar Cordeiro; Francisca Jakelyne de Farias Marques; Rebecca de Aguiar Cordeiro; Marcos Reinaldo da Silva; Angela Donato Maia Malaquias; Charlline Vládia Silva de Melo; Jair Mafezoli; Maria da Conceição Ferreira de Oliveira; Raimunda Sâmia Nogueira Brilhante; Marcos Fábio Gadelha Rocha; Tereza de Jesus Pinheiro Gomes Bandeira; José Júlio Costa Sidrim
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

5.  Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization.

Authors:  Kristy Dolan; Sara Montgomery; Bradley Buchheit; Louis Didone; Melanie Wellington; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

6.  High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections.

Authors:  Lixin Zhang; Kezhi Yan; Yu Zhang; Ren Huang; Jiang Bian; Chuansen Zheng; Haixiang Sun; Zhihui Chen; Nuo Sun; Rong An; Fangui Min; Weibo Zhao; Ying Zhuo; Jianlan You; Yongjie Song; Zhenyan Yu; Zhiheng Liu; Keqian Yang; Hong Gao; Huanqin Dai; Xiaoli Zhang; Jian Wang; Chengzhang Fu; Gang Pei; Jintao Liu; Si Zhang; Michael Goodfellow; Yuanying Jiang; Jun Kuai; Guochun Zhou; Xiaoping Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

7.  In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.

Authors:  Luana Rossato; Érico S Loreto; Régis A Zanette; Francieli Chassot; Janio M Santurio; Sydney H Alves
Journal:  Folia Microbiol (Praha)       Date:  2016-02-04       Impact factor: 2.099

8.  Anti-Candida properties of asaronaldehyde of Acorus gramineus rhizome and three structural isomers.

Authors:  Sandeep B Rajput; Ravikumar B Shinde; Madhushree M Routh; Sankunny M Karuppayil
Journal:  Chin Med       Date:  2013-09-08       Impact factor: 5.455

9.  Mutual independence of alkaline- and calcium-mediated signalling in Aspergillus fumigatus refutes the existence of a conserved druggable signalling nexus.

Authors:  Omar Loss; Margherita Bertuzzi; Yu Yan; Natalie Fedorova; Bethany L McCann; Darius Armstrong-James; Eduardo A Espeso; Nick D Read; William C Nierman; Elaine M Bignell
Journal:  Mol Microbiol       Date:  2017-11-14       Impact factor: 3.501

10.  Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.

Authors:  Maytham Hussein; Xiaohan Hu; Olivia K A Paulin; Simon Crawford; Qi Tony Zhou; Mark Baker; Elena K Schneider-Futschik; Yan Zhu; Jian Li; Tony Velkov
Journal:  Comput Struct Biotechnol J       Date:  2020-08-21       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.